试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-30
Mandibular Furcation III Regeneration (FURC-III-REGEN)
编号:NCT04059458登记状态:提前终止企业 / 申办者:University of Oslo
药物 / 成分:Biphasic calcium phosphate (Straumann Bone Ceramic) + collagen membrane (Straumann Jason Membrane)、Biphasic calcium phosphate (Straumann Bone Ceramic) + enamel matrix proteins (Straumann Emdogain)
登记的停止原因(原文):Recruitment problem
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-30
Continuous Intravenous Lidocaine Infusion Versus Placebo for Rib Fracture Analgesia
编号:NCT04140396登记状态:提前终止企业 / 申办者:Stanford University
药物 / 成分:Saline infusion、Lidocaine infusion
登记的停止原因(原文):Lack of personnel and lack of funding for the study drug
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-30
Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV
编号:NCT04249037登记状态:提前终止企业 / 申办者:University of Colorado, Denver
药物 / 成分:bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF)、Standard initiation of antiretroviral therapy (ART)
登记的停止原因(原文):Insufficient enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-29
Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors
编号:NCT01190644登记状态:提前终止企业 / 申办者:Merck Sharp & Dohme LLC
药物 / 成分:Sotatercept
登记的停止原因(原文):Isotope needed to conduct RBC/PV analysis (primary endpoint) no longer available from manufacturer. No alternatives available for use.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-29
A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia
编号:NCT03771664登记状态:提前终止企业 / 申办者:Biogen
药物 / 成分:SAGE-217、Placebo
登记的停止原因(原文):internal company decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-29
Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma
编号:NCT03867370登记状态:提前终止企业 / 申办者:Shanghai Junshi Bioscience Co., Ltd.
药物 / 成分:Toripalimab (JS001 )、Toripalimab (JS001 ) Lenvatinib、Toripalimab (JS001 ) Lenvatinib
登记的停止原因(原文):Enrollment is over, the study was completed
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-29
Study of Cilofexor in Adults With Primary Sclerosing Cholangitis
编号:NCT03890120登记状态:提前终止企业 / 申办者:Gilead Sciences
药物 / 成分:Cilofexor、Placebo
登记的停止原因(原文):Following recommendation of the external Data Monitoring Committee, after it reviewed the results of a planned interim futility analysis.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-29
A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder
编号:NCT04007367登记状态:提前终止企业 / 申办者:Biogen
药物 / 成分:SAGE-217、Placebo
登记的停止原因(原文):Internal company decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-29
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects
编号:NCT04446000登记状态:提前终止企业 / 申办者:CSL Behring
药物 / 成分:CSL730、Placebo
登记的停止原因(原文):Lack of clinical viability
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2023-11-29
Management of Angiotensin Inhibitors During the Perioperative Period
编号:NCT04506372登记状态:提前终止企业 / 申办者:UMC Utrecht
药物 / 成分:Perioperative withdrawal of angiotensin converting enzyme inhibitors and angiotenin receptor blockers、Blood draw、Diary to register drug adherence、Quality of life questionnaire
登记的停止原因(原文):slow recruitment rate
查看官方原始记录 ↗